Publications

How will FDA changes reshape drug approval in 2025 and beyond?

Quoted, Chemical & Engineering News

Chad Landmon, Hatch-Waxman & Biologics Chair, highlights concerns about the impact of recent government layoffs at the FDA, which have disrupted critical drug safety work.